Krónikus vesebetegség: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• SGLT2 24
• GLP-1 8
• NLRP3 0
• NRF2 1
• PI3K 0
• APOL1 3
• AKT 0
• STAT3 1
• mTOR 1
• PPAR 0
• AMPK 0
• SIRT1 0
• HIF-1 0
• TLR4 0
• STING 0
• MAPK 0
• CTNNB1 0
• TP53 0
• ERK 0
• GPX4 0
• IL-6 3
• VEGF 0
• IL-1 1
• JAK 0
• JNK 0
• TNF 1
• DPP-4 0
• EGFR 0
• YAP 0
• FGFR 0
• PCSK9 0
• APOE 0
• PINK1 0
• TFEB 0
• BCMA 3
• HMGB1 0
• HSP90 0
• BDNF 0
• GIP 0
• CD40 0
• CD47 0
• COX-2 0
• IL-17 1
• PKM2 0
• PSMA 0
• ABL1 0
• CCR5 0
• EZH2 0
• METTL3 0
• MMP-9 0
• PKD1 0
• PTEN 0
• SNCA 0
• ANGPTL3 0
• BCL-2 0
• CD19 1
• CD38 0
• CDK4/6 0
• CXCR4 0
• FTO 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 500 000 EUR· until 2032. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finnország· EU contribution 4 273 568 EUR· until 2031. jan.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Formaldehyde crosslink exposure and genomic ageing (FORCE)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 2 693 628 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)

  Universite Paris Cite· Paris, Franciaország· EU contribution 1 498 100 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Direct implication of the Calcium Sensing Receptor in Vascular Calcifiction and Atherosclerosis in Chronic Kidney Disease (AtheroCaSR)

  Cardiff University· Cardiff, Egyesült Királyság· EU contribution 325 435 EUR· until 2029. febr.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting Glutamine (Q) Metabolism in the Renal Ciliopathies (QrCiliopathies)

  Ospedale San Raffaele Srl· Milano, Olaszország· EU contribution 150 000 EUR· until 2028. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Transforming Haemodialysis Safety with a Graphene Light-Activated Antimicrobial Device (SAFE-HD)

  GO Antimicrobial Technologies, Lda· Porto, Portugália· EU contribution 500 000 EUR· until 2028. júl.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  LOKI: Loiasis-associated chronic kidney disease – towards clinical recognition and policy action

  Institut de Recherche Pour Le Developpement· Marseille, Franciaország· EU contribution 150 000 EUR· until 2027. nov.

• European Commission (Horizon Europe) · HORIZON-RIA

  Mechanism-Informed Multimodal Generative AI for Causal and Dynamical Modelling in Biomedical Research (AIRIS)

  Athina-Erevnitiko Kentro Kainotomias Stis Technologies Tis Pliroforias, Ton Epikoinonion Kai Tis Gnosis· Maroussi, Görögország· EU contribution 16 944 729 EUR· until 2030. máj.· 11 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  From uremic toxins to cognitive decline: Elucidating the pathophysiology of mild cognitive impairment in chronic kidney disease (MOMENTUM)

  BIOGEM scarl· Ariano Irpino (Av), Olaszország· EU contribution 5 999 488 EUR· until 2030. máj.· 10 countries

10 of 52 running projects, newest first. Listed amounts together: 145,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 29
• Organoids 10
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 5
• Gene Expression Profiling 88
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 19
• Proteomics 103
• Metabolomics 91
• Mass Spectrometry 18
• Flow Cytometry 10
• Immunohistochemistry 19
• Liquid Biopsy 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 70
• Machine Learning 176
• Deep Learning 22
• Cohort Studies 553
• Genome-Wide Association Study 79

• Integrated transcriptomic analysis and machine learning identify AURKA and CENPM as candidate biomarkers in focal segmental glomerulosclerosis.

  PLoS One, 2026. nov.

• Vitamin B12 Intake and Diabetic Kidney Disease: A NHANES-Based Cross-Sectional Study with Transcriptomic Identification of P2RY14.

  J Vis Exp, 2026. okt.

• Distinct Molecular Relationships and Partial Pathway Convergence of Anserine and RRR-α-Tocopherol in Human Diabetic Kidney Disease.

  Int J Mol Sci, 2026. okt.

• Mean-Centering Alters Pathway-Based Transcriptomic Comparisons of Feline and Mouse Kidney Disease.

  Int J Mol Sci, 2026. okt.

• Analysis of end-stage renal disease mediated by cuproptosis-related genes.

  Clin Nephrol, 2026. okt.

• Characterizing the Transcriptional Features That Underlie Established Injury and Disease Progression in Diabetic Kidney Disease.

  Kidney360, 2026. szept.

• A hypoxia-derived seven-gene signature reflects immune remodeling in diabetic kidney disease: integrated transcriptomic analysis and experimental validation.

  Diabetes Res Clin Pract, 2026. szept.

• Alterations of Gene Expression and Signaling Pathway Activity in Venous Smooth Muscle Cells After Uremic Serum Exposure.

  Int J Mol Sci, 2026. szept.

• Multi-omics and machine learning reveal LYZ and ISG15 as diagnostic and therapeutic targets in autoimmune-mediated chronic kidney disease.

  Front Immunol, 2026. szept.

• Integrative multi-omics analysis prioritizes compartment-specific candidate targets of gut microbiota metabolites in diabetic kidney disease.

  Front Immunol, 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.